5-fluorouracil: Synchronous application of continuous and bolus therapy in heavily pretreated metastatic colorectal cancer: A phase I/II study

Onkologie

Volumn 23, Issue 2, 2000, Pages 128-132

  Oettle, Helmut ^a   Meyer, L ^b   Bechstein, W O ^b   Riess, H ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b NONE

Author keywords

5 Fluorouracil; Continuous infusion; Metastatic colorectal carcinoma

Indexed keywords

FLUOROURACIL;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; FEMALE; HUMAN; INFUSION PUMP; MALE; MUCOSA INFLAMMATION; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; VOMITING;

EID: 0034081619     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000027091     Document Type: Article

References (17)

1. Heidelberger C, Chaudhuri NK, Danneberg P, Moorln D, Griesbach L, Duschinsky R, Schnitzler RJ, Pleven E, Scheiner J: Fluorinated pyrimidine. A new class of tumor-inhibitory compounds. Nature 1957; 179:663-666.
2. Machover D: A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer 1997;80:1179-1187.
3. Aschele C, Sobrero A, Faderan MA, Bertino JR: Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 1992;52:1855-1864.
4. Mori A, Bertoglio S, Guglielmi A, Aschele C, Bolli E, Tixi L, Rosso R, Sobrero A: Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil. Cancer Chemother Pharmacol 1993;33: 179-180.
5. Sobrero AF, Aschele C, Bertino JR: Fluorouracil in colorectal cancer - A tale of two drugs: Implications for biochemical modulation. J Clin Oncol 1997;15: 368-381.
6. Ardalan B, Chua L, Tian E, Reddy R, Sridhar K, Benedetto P, Richman S, Legaspi A, Waldman S, Morrell L, Feun L, Savaraj N, Livingstone A: A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Oncol 1991;9:625-630.
7. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic oncology program study. J Clin Oncol 1989;7:425-432.
8. Sobrero AF, Aschele C, Guglielmi AP, Mori AM, Melioli GG, Rosso R, Bertino JR: Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. J Natl Cancer Inst 1993;85: 1937-1944.
9. Harstrick A, Gonzales A, Vanhoefer U, Hoffmann A, Seeber S, Wilke H: Development and characterization of 5-FU resistant cell lines showing schedule dependent resistance mechanisms. Onkologie 1994;17(suppl 2):54.
10. de Gramont A, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, Morvan F, Louvet C, Guillot T, Françoise E, Bedenne L: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup Study. J Clin Oncol 1997;15:808-815.
11. Sobrero AF, Aschele C, Guglielmi AP, Mori AM, Tixi LM, Bolli EA, Rosso R, Mammoliti S, Rollandi GA, Bertoglio S, Bruzzi P, Bertino JR: Schedule-selective biochemical modulation of 5-fluorouracil: A phase II study in advanced colorectal cancer. Clin Cancer Res 1995;1:955-960.
12. Machover D, Diaz-Rubio E, de-Gramont A, Schilf A, Gastiaburu JJ, Brienza S, Itzhaki M, Metzger G, N'Daw D, Vignoud J, Abad A, François E, Gamelin E, Marty M, Sastre J, Seitz JF, Ychou M: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996;7:95-98.
13. Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, Macdonald JS, Geyer CE Jr, Sandbach J, Wolf DL, Mohrland JS, Elfring GL, Miller LL, Von-Hoff DD: A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999;85:786-795.
14. Weh HJ, Wilke HJ, Dierlamm J, Klaassen U, Siegmund R, Illiger HJ, Schalhorn A, Kreuser ED, Hilgenfeld U, Steinke B, Weber W, Burkhard O, Zoller A, Pfitzner J, Subert R, Kriebel R, Hossfeld DK: Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 1994;5:233-237.
15. Jäger E, Klein O, Wächter B, Müller B, Braun U, Knuth A: Second-line treatment with high-dose 5-fluorouracil and folinic acid in advanced colorectal cancer refrectory to standard-dose 5-fluorouracil treatment. Oncology 1995;52:470-473.
16. Stoffregen C, Zurborn K-H, Boehme V, Schmid A, Lorenz G, Arendt T, Fölsch UR: Weekly high-dose 5-fluorouracil 24-hour infusion and intermediate-dose folinic acid bolus in metastatic colorectal cancer. Onkologie 1996;19:410-414.
17. Köhne CH, Schöffski P, Wilke H, Käufer C, Andreesen R, Ohl U, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Harstrick A, Bade J, Horster A, Schubert U, Hecker H, Dörken B, Schmoll HJ: Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 1998;16: 418-426.